Advances in monitoring IBD treatment are discussed elsewhere in the May 2025 issue. To complement the coverage, Pathology in Practice Science Editor Brian Nation selects a small sample of peer-reviewed research in this area of gastroenterology.
Omics and Multi-Omics in IBD: No Integration, No Breakthroughs
Fiocchi C. Int J Mol Sci. 2023 Oct 5; 24(19):14912. doi: 10.3390/ijms241914912.
The recent advent of sophisticated technologies like sequencing and mass spectroscopy platforms combined with artificial intelligence-powered analytic tools has initiated a new era of ‘big data’ research in various complex diseases of still-undetermined cause and mechanisms. The investigation of these diseases was, until recently, limited to traditional in vitro and in vivo biological experimentation, but a clear switch to in silico methodologies is now under way.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.